SLAM
XERS icon

Swiss Life Asset Management’s Xeris Biopharma Holdings XERS Stock Holding History

Swiss Life Asset Management’s Portfolio XERS Stock Details XERS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-33,232
Closed -$789K – 1745
2026
Q1 		$789K Buy
33,232
+7,173
+28% +$47.6K ﹤0.01% 712
2025
Q4 		$205K Buy
+26,059
New +$205K ﹤0.01% 1275

Other funds holding XERS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
RA
Rosalind Advisors Toronto, Ontario, Canada $269M AUM 103.38% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Swiss Life Asset Management's XERS Position: Q2 2026 in Review

Swiss Life Asset Management sold out of Xeris Biopharma Holdings (XERS) in Q2 2026, closing a stake of 33,232 shares — an estimated $789K sold.

Swiss Life Asset Management first reported a position in XERS in Q4 2025 and held it in 2 quarters. The position peaked at $789K in Q1 2026. 240 funds tracked by Wall St. Rank hold XERS as of Q2 2026.

  • Swiss Life Asset Management reported no remaining Xeris Biopharma Holdings position as of Q2 2026 after selling out during the quarter.
  • Swiss Life Asset Management sold 33,232 Xeris Biopharma Holdings shares in Q2 2026, an estimated $789K.
  • Swiss Life Asset Management first reported a position in Xeris Biopharma Holdings in Q4 2025 and held it in 2 quarters.
  • Swiss Life Asset Management's Xeris Biopharma Holdings position peaked at $789K in Q1 2026.
  • 240 funds tracked by Wall St. Rank held Xeris Biopharma Holdings as of Q2 2026.

Based on Swiss Life Asset Management's 13F filing for Q2 2026, filed 29 Jul 2026.